Design and Development of Novel Mini Tablet Cap Technology for the Treatment of Cardiovascular Diseases

Q4 Pharmacology, Toxicology and Pharmaceutics

International Journal of Drug Delivery Technology Pub Date : 2023-09-25 DOI:10.25258/ijddt.13.3.04

Anil K. Adimulapu, Lalchand D. Devhare, Anasuya Patil, Nilesh O. Chachda, G. Dharmamoorthy

{"title":"Design and Development of Novel Mini Tablet Cap Technology for the Treatment of Cardiovascular Diseases","authors":"Anil K. Adimulapu, Lalchand D. Devhare, Anasuya Patil, Nilesh O. Chachda, G. Dharmamoorthy","doi":"10.25258/ijddt.13.3.04","DOIUrl":null,"url":null,"abstract":"Objectives: The purpose of the investigation was to extend and evaluate the novel mini tablet cap for treating cardiovascular disease at a desired combinational therapeutic activity and to improve patient compliance. A cheap four-in-one pill can guard against heart attacks and stroke. Methods and Materials: The drug product was manufactured by mini tablet cap technology. The technology was designed to initially use hydrochlorothiazide, simvastatin immediate release, metoprolol succinate, and asprin sustained release to reach the therapeutic levels at prolonged therapy. The two mini-bilayer tablets were prepared by wet granulation method and compression coated with a hydrophobic and hydrophilic polymer like ethyl cellulose and super disintegrating agents to release simvastatin and hydrochlorothiazide immediately. Results: Fourier transformer infrared spectroscopy (FTIR) studied the interaction studies of four chosen drugs. The mini tablet cap technology was designed as two mini bi-layer tablets in a capsule. The quantitative detection of four individual drugs was determined by using the RP-HPLC method. It was found that RP-HPLC is sensitive, reproducible, and valid for determining the mini tablet cap. The in-vitro drug release studies found that simvastatin and hydrochlorothiazide release 90% immediately within 20 minutes. Metoprolol and aspirin controlled the release for up to 24 hours, and drug release kinetics found that the drug release behavior of the optimized formulation followed first-order kinetics. Conclusion: The mini tablet cap is one of the best dosage forms to treat cardiovascular diseases. Because it was reported, the combination of these four drugs reduces mortality by 83% in high-risk patients with heart diseases, hypertension, diabetes, and obesity. The novel mini tablet cap approach data revealed a promising formula for improved relief of patient complaints during treatment or prevention of cardiovascular diseases","PeriodicalId":13851,"journal":{"name":"International Journal of Drug Delivery Technology","volume":"27 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Drug Delivery Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25258/ijddt.13.3.04","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The purpose of the investigation was to extend and evaluate the novel mini tablet cap for treating cardiovascular disease at a desired combinational therapeutic activity and to improve patient compliance. A cheap four-in-one pill can guard against heart attacks and stroke. Methods and Materials: The drug product was manufactured by mini tablet cap technology. The technology was designed to initially use hydrochlorothiazide, simvastatin immediate release, metoprolol succinate, and asprin sustained release to reach the therapeutic levels at prolonged therapy. The two mini-bilayer tablets were prepared by wet granulation method and compression coated with a hydrophobic and hydrophilic polymer like ethyl cellulose and super disintegrating agents to release simvastatin and hydrochlorothiazide immediately. Results: Fourier transformer infrared spectroscopy (FTIR) studied the interaction studies of four chosen drugs. The mini tablet cap technology was designed as two mini bi-layer tablets in a capsule. The quantitative detection of four individual drugs was determined by using the RP-HPLC method. It was found that RP-HPLC is sensitive, reproducible, and valid for determining the mini tablet cap. The in-vitro drug release studies found that simvastatin and hydrochlorothiazide release 90% immediately within 20 minutes. Metoprolol and aspirin controlled the release for up to 24 hours, and drug release kinetics found that the drug release behavior of the optimized formulation followed first-order kinetics. Conclusion: The mini tablet cap is one of the best dosage forms to treat cardiovascular diseases. Because it was reported, the combination of these four drugs reduces mortality by 83% in high-risk patients with heart diseases, hypertension, diabetes, and obesity. The novel mini tablet cap approach data revealed a promising formula for improved relief of patient complaints during treatment or prevention of cardiovascular diseases

查看原文本刊更多论文

治疗心血管疾病的新型微型片头技术的设计与开发

目的:研究的目的是扩展和评估在理想的联合治疗活性下治疗心血管疾病的新型迷你片帽，并提高患者的依从性。一种便宜的四合一药片可以预防心脏病发作和中风。方法与材料:采用微型片盖工艺制备本品。该技术最初使用氢氯噻嗪、辛伐他汀速释、琥珀酸美托洛尔和阿司匹林缓释，在延长治疗时达到治疗水平。采用湿造粒法制备两种微型双层片，并包被疏水性和亲水性聚合物如乙基纤维素和超级崩解剂，可使辛伐他汀和氢氯噻嗪立即释放。结果:傅里叶变换红外光谱(FTIR)研究了所选药物的相互作用。迷你片帽技术设计为两片迷你双层片剂装在一个胶囊中。采用反相高效液相色谱法对四种药物进行定量检测。发现反相高效液相色谱法测定迷你片剂药帽灵敏度高，重现性好，有效。体外释药研究发现辛伐他汀和氢氯噻嗪在20分钟内立即释放90%。美托洛尔和阿司匹林的释放控制时间长达24小时，药物释放动力学发现优化制剂的药物释放行为符合一级动力学。结论:微型片盖是治疗心血管疾病的最佳剂型之一。因为据报道，这四种药物联合使用可使心脏病、高血压、糖尿病和肥胖症高危患者的死亡率降低83%。新型迷你片剂帽方法数据揭示了一个有希望的公式，以改善缓解患者的投诉在治疗或预防心血管疾病

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Drug Delivery Technology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

0.70

自引率

0.00%

发文量

期刊介绍： International Journal of Drug Delivery Technology (IJDDT) provides the forum for reporting innovations, production methods, technologies, initiatives and the application of scientific knowledge to the aspects of pharmaceutics, including controlled drug release systems, drug targeting etc. in the form of expert forums, reviews, full research papers, and short communications.